Designing Bioequivalence Studies for Locally Acting Drugs: Regulatory and Clinical Considerations

Published on 21/12/2025

How to Design BE Studies for Locally Acting Drug Products

Table of Contents

Introduction: Why Locally Acting Drugs Need Special Study Designs

Unlike systemically absorbed drugs where bioequivalence (BE) is established through pharmacokinetic (PK) parameters like C_max and AUC, locally acting drug products require unique BE study designs. These drugs—such as ophthalmic drops, nasal sprays, dermatological creams, inhalers, and gastrointestinal (GI)-acting formulations—are intended to exert their effect directly at the site of application, with minimal or no systemic absorption.

This creates challenges in proving bioequivalence, since conventional blood-based PK studies may not reflect the actual local therapeutic performance. Regulatory agencies like the FDA, EMA, and CDSCO require tailored study designs using clinical, pharmacodynamic, or in vitro methodologies. This article walks through the design considerations and strategies for BE assessment of locally acting drugs.

Categories of Locally Acting Drugs

Locally acting drugs cover a wide range of dosage forms and administration routes:

Topical dermatologicals: creams, ointments, gels
Ophthalmic products: eye drops, suspensions
Inhalation products: metered-dose inhalers (MDIs), dry powder inhalers (DPIs)
Nasal sprays: for rhinitis or allergy management
GI-acting oral formulations: mesalamine, budesonide
Rectal/vaginal formulations: suppositories, foams

Each of these requires different BE strategies depending on the site of action, formulation complexity,

and feasibility of endpoint measurement.

Limitations of Standard PK Approach

Systemic PK studies are often not suitable for locally acting products due to:

Minimal systemic absorption (e.g., topical corticosteroids)
PK does not correlate with local efficacy
Measuring plasma concentrations does not reflect local exposure
Inter-subject variability obscures local performance

Therefore, regulators require alternative BE demonstration methods such as clinical endpoint studies, pharmacodynamic (PD) assessments, or in vitro comparisons.

Design Options for BE Studies of Locally Acting Products

1. Clinical Endpoint Studies:

Used when no measurable PK or PD marker exists
Comparative efficacy and/or safety trials in patients
Often conducted as randomized, double-blind, parallel-group designs
Example: Acne treatment creams evaluated based on lesion count reduction

2. Pharmacodynamic Studies:

Measure local physiological response (e.g., vasoconstriction in corticosteroids)
Shorter and smaller than clinical endpoint studies
Applicable only when PD effect is well-characterized

3. In Vitro Studies:

Used when product is a solution or simple suspension
Include dissolution, particle size, viscosity, pH, spray pattern, droplet size
Highly preferred for nasal, ophthalmic, and topical solution formulations
May fully waive in vivo BE requirements under Q1/Q2 sameness conditions

Regulatory Pathways and Agency-Specific Requirements

FDA (U.S.):

Requires Q1/Q2 sameness, device equivalence (if applicable), and route-specific in vitro or in vivo testing
Supports in vitro-only BE for ophthalmic and nasal aqueous solutions under certain conditions
Provides product-specific guidances (PSGs) outlining BE expectations

EMA (Europe):

Prefers in vitro data where feasible but often requires clinical endpoint studies
Focuses on comparative local tolerability and performance
Allows extrapolation if mechanistic rationale is strong

CDSCO (India):

Often mirrors EMA and WHO guidance
Emphasizes ethical approval and risk-benefit justification for clinical endpoint studies
Encourages sponsors to follow globally accepted BE pathways

Case Example: Nasal Spray BE Study

A sponsor developed a generic fluticasone nasal spray and aimed to waive clinical endpoint studies by demonstrating in vitro equivalence. Product met the following criteria:

Q1/Q2 sameness to RLD
Identical device and spray actuator
Comparable plume geometry, droplet size, spray pattern, dose uniformity

Outcome: FDA granted full waiver of in vivo study requirement, based on in vitro-only BE data, reducing development time and cost.

Challenges and Ethical Considerations

Clinical endpoint studies are expensive, require large sample sizes, and pose ethical concerns—especially if placebo arms are included. For example:

Subjectivity in endpoints (e.g., itch relief, visual clarity)
Placebo control may not be ethical in serious conditions
Trial blinding is difficult when formulations differ in texture, smell, or application

Therefore, choosing in vitro or PD approaches whenever possible is both ethically and economically favorable.

Best Practices for BE Protocol Design

Start with regulatory review of product-specific guidances (PSGs or EMA templates)
Justify selection of BE approach (in vitro, PD, or clinical)
Use validated instruments and scoring systems for subjective endpoints
Design endpoint studies with adequate power (usually >80%)
Ensure batch-to-batch consistency in Test and Reference products
Maintain detailed documentation on manufacturing, formulation, and device equivalency

Conclusion: Tailored Designs Ensure Locally Acting Drug Approval

Locally acting drug products demand customized bioequivalence strategies that go beyond standard PK assessments. Whether using in vitro tests, PD markers, or clinical endpoint studies, sponsors must align with regulatory expectations and scientific rationale to build a strong BE case.

As global agencies increasingly support biowaivers for non-systemic drugs, careful product characterization, device equivalence, and rigorous protocol design can significantly reduce time-to-approval and cost. Ultimately, success in locally acting BE studies lies in selecting the right design for the right drug.